MENLO PARK, Calif., March 13, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will share scientific data at the 55th Annual Meeting of the Society of Toxicology (SOT), which will suggest the company's novel topical gel BPX-01 delivers acne-fighting medication to the target area safely without systemic side effects.
A poster on the research, titled "BPX-01 Toxicological Evaluation of 1% Topical Minocycline Gel," will be presented at the Baltimore meeting from 1:15 p.m. to 4:30 p.m. on March 14 (poster number P511). The SOT meeting is one of the world's largest gatherings of toxicologists.
Oral minocycline is a routinely prescribed antibiotic for the treatment of acne, but because it delivers the active drug systemically, there can be undesirable side effects, such as upset stomach, diarrhea, dizziness and headache. BPX-011 is the first fully solubilized and stable topical gel formulation of minocycline, which had previously been demonstrated to penetrate the skin and to the pilosebaceous unit where acne develops. BPX-01 may improve bioavailability and enable the use of a lower dosage of the drug, which pre-clinical and clinical studies suggest thus far does not enter the blood system in measurable quantities.
"One of the issues that concerns me the most with our current treatment options for moderate-to-severe acne is the systemic exposure to antibiotics, which can lead to antibiotic resistance and other unwanted side effects," said Dr. Joely Kaufman, board certified dermatologist and investigator for the BioPharmX Phase 2b study of BPX-01. "In my practice I try to minimize the length of time a patient is on oral antibiotics to avoid systemic side effects."
"The research to date suggests that BPX-01 topical gel delivers low but potentially efficacious dosages of minocycline to target areas," said Kin F. Chan, executive vice president of research and technology at BioPharmX. "BPX-01 offers promise to millions of people who cannot take oral minocycline to treat their acne, including young children, pregnant women and the many people who are intolerant of systemic antibiotic treatments."
This is the second year BioPharmX is appearing at the SOT meeting. Last year, company researchers shared non-clinical safety and toxicokinetic data for BPX-01. This year's presentation provides an overview of the non-clinical program with special focus on the study data from longer drug exposures with comparisons to the earlier data.
BioPharmX is currently conducting the OPAL (tOPicAL Minocycline Gel) study – a Phase 2b dose finding clinical trial to assess the efficacy and safety of BPX-01 for the treatment of acne vulgaris. The 12-week, multi-center, randomized, double-blind, three-arm, vehicle-controlled study involves 225 individuals, aged 9 to 40, who have moderate-to-severe inflammatory, non-nodular acne vulgaris.
The American Academy of Dermatology calls acne the "most common skin condition in the United States," affecting 40 million to 50 million Americans. The U.S. market for prescription acne medications is estimated at $4 billion.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company that seeks to provide products through proprietary platform technologies for prescription, over-the-counter and supplement applications in dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statement
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions and strategies, including, but not limited to, statements regarding, the safety and medical effects of BPX-01, the effect BPX-01 may have on the treatment of acne, whether minocycline's anti-inflammatory properties may be delivered in a topical formulation to target P. acnes-stimulated sebocytes, commencement and results of future tests involving BPX-01, continued and consistent results in future tests of BPMX-01 and absence of side effects of future use of BPX-01. These forward-looking statements may be identified by words such as "may", "plan", "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
BioPharmX is a registered trademark of BioPharmX, Inc.
1 Caution: BPX-01 is a new drug limited by U.S. law to investigational use.
SOURCE BioPharmX Corporation